CytomyX Therapeutics

CytomX Therapeutics is a clinical-stage oncology-focused biopharmaceutical company pioneering the field of conditionally activated biologics. The company’s proprietary Probody® platform technology is designed to exploit unique conditions within the tumor microenvironment, such as high protease activity, to localize biological activity to tumors while minimizing toxicities in healthy tissues. Their pipeline includes a diverse range of therapeutic candidates, including antibody-drug conjugates (ADCs), bispecific T-cell engagers, and immune-modulators. These programs are developed both independently and in collaboration with major pharmaceutical partners like Bristol Myers Squibb, Amgen, and Astellas. By masking the active site of antibodies until they reach the tumor, CytomX aims to expand the therapeutic window of potent biologics that were previously limited by systemic side effects.